Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Inappropriate cathepsin K secretion promotes its enzymatic activation driving heart and valve malformation
Po-Nien Lu, Trevor Moreland, Courtney J. Christian, Troy C. Lund, Richard A. Steet, Heather Flanagan-Steet
Po-Nien Lu, Trevor Moreland, Courtney J. Christian, Troy C. Lund, Richard A. Steet, Heather Flanagan-Steet
View: Text | PDF
Research Article Cell biology Development

Inappropriate cathepsin K secretion promotes its enzymatic activation driving heart and valve malformation

  • Text
  • PDF
Abstract

Although congenital heart defects (CHDs) represent the most common birth defect, a comprehensive understanding of disease etiology remains unknown. This is further complicated since CHDs can occur in isolation or as a feature of another disorder. Analyzing disorders with associated CHDs provides a powerful platform to identify primary pathogenic mechanisms driving disease. Aberrant localization and expression of cathepsin proteases can perpetuate later-stage heart diseases, but their contribution toward CHDs is unclear. To investigate the contribution of cathepsins during cardiovascular development and congenital disease, we analyzed the pathogenesis of cardiac defects in zebrafish models of the lysosomal storage disorder mucolipidosis II (MLII). MLII is caused by mutations in the GlcNAc-1-phosphotransferase enzyme (Gnptab) that disrupt carbohydrate-dependent sorting of lysosomal enzymes. Without Gnptab, lysosomal hydrolases, including cathepsin proteases, are inappropriately secreted. Analyses of heart development in gnptab-deficient zebrafish show cathepsin K secretion increases its activity, disrupts TGF-β–related signaling, and alters myocardial and valvular formation. Importantly, cathepsin K inhibition restored normal heart and valve development in MLII embryos. Collectively, these data identify mislocalized cathepsin K as an initiator of cardiac disease in this lysosomal disorder and establish cathepsin inhibition as a viable therapeutic strategy.

Authors

Po-Nien Lu, Trevor Moreland, Courtney J. Christian, Troy C. Lund, Richard A. Steet, Heather Flanagan-Steet

×

Figure 6

Ctsk deficiency alters valve and myocardial development.

Options: View larger image (or click on image) Download as PowerPoint
Ctsk deficiency alters valve and myocardial development.
(A) Confocal im...
(A) Confocal images of tie2:EGFP embryos treated with odanacatib show alterations in both myocardia (red) and valves (green). In particular, the atria of Ctsk-inhibited hearts are smaller, and the valve cells are less organized. The white line denotes the defined layers present in the WT valve. Percent values represent the number of animals exhibiting these phenotypes. n = 20 embryos from 3 independent experiments. Scale bar: 30 μm (left panels) and 10 μm (right panels). (B) Quantification of the number of control and odanacatib-treated embryos whose hearts “loop” and valves open and close (“clap”) at regular intervals. Each dot represents an experiment with 25 embryos, with 100 total embryos scored. (C) The cross-sectional area of the ventricles and atria is shown from n = 15–20 embryos. Data are presented as mean ± SEM; **P < 0.01,***P < 0.001 by 2-tailed Student’s t test or Dunnett’s corrected test (denoted by red box). V, ventricle; A, atrium. (D) In situ analyses of notch1b expression show reduced expression in AV valves of odanacatib-treated embryos (red arrow heads). Percent values represent the number of animals exhibiting these phenotypes. n = 30 embryos from 3 independent experiments. Scale bar: 50 μm. (E) Schematic depicts TALEN targeted sequences in ctsk, resulting INDELS, and genotyping strategy. Black arrowheads denote position of genotyping primers. (F) Restriction enzyme–based genotyping of PCR amplified samples that were left “uncut” (UC) or “cut” with the HaeIII restriction enzyme. (G) Confocal images of WT and ctsk mutants stained immunohistochemically for myosin (using MF20, red) show reduced size of atria in embryos homozygote for the 2 bp–deleted allele. Percent values represent the number of animals exhibiting these phenotypes. n = 30 embryos imaged from 3 independent experiments. Scale bar: 30 μm. (H) quantification of cross-sectional area of ventricles and atria in WT and ctsk-compromised embryos. Data are presented as mean ± SEM. ***P < 0.001, ****P < 0.0001 using 2-tailed Student’s t test or Dunnett’s corrected test (denoted by red box). (I) In situ analyses of notch1b expression show its boundary is expanded in AV and OFT valves (white arrowheads) of ctsk2bp/2bp embryos (red arrow heads). Percent values represent the number of animals exhibiting these phenotypes. n = 25–30 embryos from 3 independent experiments. Scale bar: 50 μm.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts